Brief: Neurizon's NUZ-001 Reduces Aggregation Of Key ALS Disease Target TDP-43 In Preclinical Study
19/11/2024 10:41
Nov 19 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX :
* NEURIZON'S NUZ-001 REDUCES AGGREGATION OF KEY ALS DISEASE
TARGET
TDP-43 IN PRECLINICAL STUDY
Source text: ID:nPreDpYn6a
Further company coverage: NUZ.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility